Exploristics Secures $30 Million in Funding to Revolutionize Clinical Development with Innovative Software Solutions

Exploristics, a leading global provider of specialized software and technology-enabled services for the pharmaceutical, biotechnology, and medical device sectors, has successfully raised $30 million in its latest funding round. This significant investment will enable Exploristics to enhance its innovative capabilities, particularly focusing on the further development and optimization of its cloud-based study simulation platform, KerusCloud. Known for its state-of-the-art statistical consultancy and biostatistics services, Exploristics is committed to streamlining clinical trial processes for organizations of all sizes. The funding will specifically target advancements in KerusCloud, which serves as a critical tool for designing smarter clinical studies. By allowing users to simulate various study scenarios in a virtual environment, the platform effectively identifies the key drivers of study success, ultimately improving trial outcomes. The real-world impact of KerusCloud has been notable, as it significantly de-risks clinical studies by optimizing uncertainties, thereby reducing development timelines, costs, and patient burden. With this new funding, Exploristics aims to strengthen its research and development efforts to transform clinical development approaches, accelerating the delivery of new therapeutics to patients with unmet clinical needs. As the company continues to innovate at the intersection of data science and clinical research, it remains dedicated to providing valuable insights and solutions that empower clinical researchers and foster better health outcomes across the globe.